Flublok Quadrivalent vaccine — Competitive Intelligence Brief

Flublok Quadrivalent vaccine (Flublok Quadrivalent vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant protein vaccine Influenza hemagglutinin (HA) antigen Immunology / Infectious Disease Biologic

Target snapshot

Flublok Quadrivalent vaccine (Flublok Quadrivalent vaccine) — Tan Tock Seng Hospital. Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates immune response against four strains of influenza virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Flublok Quadrivalent vaccine TARGET	Flublok Quadrivalent vaccine	Tan Tock Seng Hospital	phase 3	Recombinant protein vaccine	Influenza hemagglutinin (HA) antigen
FluBlok	FluBlok	The University of Hong Kong	marketed	Recombinant protein vaccine	Influenza hemagglutinin (HA)
Licensed seasonal influenza vaccine	Licensed seasonal influenza vaccine	Novavax	marketed	Recombinant protein vaccine with adjuvant	Influenza hemagglutinin (HA) protein
Recombinant influenza hemagglutinin	Recombinant influenza hemagglutinin	Vaxine Pty Ltd	marketed	Recombinant protein vaccine	Influenza hemagglutinin
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)
Meningococcal B (Bexsero)	Meningococcal B (Bexsero)	University of Sao Paulo General Hospital	marketed	Recombinant protein vaccine	Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins)
Licensed 4CMenB vaccine	Licensed 4CMenB vaccine	University of Adelaide	marketed	Recombinant protein vaccine	Neisseria meningitidis serogroup B surface antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine class)

1. GlaxoSmithKline · 6 drugs in this class
2. Novavax · 5 drugs in this class
3. Vaxine Pty Ltd · 2 drugs in this class
4. D'Or Institute for Research and Education · 2 drugs in this class
5. Protein Sciences Corporation · 2 drugs in this class
6. Henogen · 1 drug in this class
7. Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 drug in this class
8. Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in this class
9. National Vaccine and Serum Institute, China · 1 drug in this class
10. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 drug in this class